Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms of schizophrenia: implications for psychobiological subtyping

Psychological Medicine - Tập 17 Số 1 - Trang 39-48 - 1987
Man Mohan Singh1, Stanley R. Kay1, Lewis A. Opler1
1Schizophrenia Research Program, Springfield, Illinois, Department of Psychiatry, Albert Einstein College of Medicine, New York, USA.

Tóm tắt

SynopsisIn three studies of comparable design, 47 schizophrenics received anticholinergic anti-Parkinsonism (AP) medications for two to four weeks along the course of neuroleptic treatment. Clinical ratings during the AP phase were contrasted against the preceding and following two-week periods on neuroleptic alone, and these changes were analysed for a total of 27 psychopathology dimensions and for clusters of seven positive and seven negative symptoms. Schizophrenics overall exhibited significant exacerbation of total psychopathology, and positive but not negative symptoms. Only those with a predominantly positive syndrome when drug-free were susceptible to AP therapeutic reversal. However, other subgroup analyses revealed worsening of total psychopathology and positive symptoms among catatonic, schizophreniform, chronic, and good outcome cases, but negative symptoms alone were significantly increased among paranoids. The results were not supportive of a positive–negative dichotomy of schizophrenia, but instead suggested a tripartite model: a distinct paranoid group and a division of the non-paranoids into a positive and a negative type.

Từ khóa


Tài liệu tham khảo

10.1007/978-1-4684-1218-5_9

Spitzer, 1978, Research Diagnostic Criteria (RDC) for a Selected Group of Functional Disorders

Singh, 1976, Wheat gluten – schizophrenia findings, Science, 194, 449, 10.1126/science.194.4263.449

10.1159/000117643

10.1017/S0033291700047942

10.1016/0010-440X(84)90080-4

10.1016/0165-1781(81)90046-9

10.1007/BF00421208

Singh, 1979, Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis, Biological Psychiatry, 14, 277

10.1159/000117667

10.1093/schbul/4.1.3

10.1097/00005053-198406000-00002

10.1111/j.1600-0447.1965.tb04996.x

10.1016/0010-440X(86)90003-9

Langfeldt, 1939, Schizophreniform States: A Katamnestic Study Based on Individual Re-examinations

Kay, 1986, Significance of positive and negative syndromes in chronic schizophrenia, British Journal of Psychiatry, 148

Kay, 1979, Cognitive abnormality in schizophrenia: A dual-process model, Biological Psychiatry, 14, 155

10.1016/0024-3205(84)90054-7

10.1192/bjp.134.1.39

Haase, 1962, Intensity and equivalence of neuroleptic effect and its therapeutic importance, Nervenarzt, 33, 213

10.1007/978-1-349-05932-4_8

10.1111/j.2044-8260.1975.tb00195.x

Davis, 1977, Neuroregulators and Psychiatric Disorders, 434

10.1126/science.504988

10.1097/00005053-197504000-00005

Singh, 1982, Psychobiology of Schizophrenia, 93

10.1097/00005053-198203000-00004

10.1016/S0140-6736(78)90193-9

10.2466/pms.1975.40.1.178

10.1007/BF00433802

Shakow, 1977, Schizophrenia, Selected Papers

10.1097/00005053-198108000-00006

Magaro, 1983, Hemispheric preference of paranoid and nonparanoid schizophrenics, Biological Psychiatry, 18, 1269

10.1007/BF00421012

Spitzer, 1969, Psychiatric Evaluation Form – R2. Manual of Instructions

10.1111/j.1600-0447.1960.tb07611.x

10.1192/bjp.125.2.146

Crow, 1980, Positive and negative schizophrenic symptoms and the role of dopamine, British Journal of Psychiatry, 137, 383, 10.1192/S0007125000071919

1980, Diagnostic and Statistical Manual of Psychiatric Disorders

10.1007/BF00421013

10.1126/science.7350667

Slater, 1969, Clinical Psychiatry

10.2466/pr0.1962.10.3.799

Thông tin
Thông tin xuất bản

Psychological Medicine

Tập 17 Số 1

39-48

Thông tin tác giả